Investment research report for ATRI

Table of Contents

Executive Summary
Valuation Analysis
Industry and Competitors Analysis
Financial Analysis
Earnings Call Multi-Year Analysis
Financial Statements Multi Year
Insider Trading Analysis
Management Compensation Benchmark Analysis
Proxy Statement Analysis
News Analysis
Technical Indicators Analysis
Financial Statements Annual
Financial Statements Quarterly
Earnings Call Analysis

Executive Summary

Company Description

Atrion Corporation (ATRI) is a leading medical device company that specializes in fluid delivery, cardiovascular, and ophthalmology products. With a strong focus on innovation and quality, ATRI has established a reputation for developing reliable and effective medical devices used in various healthcare settings.

Financial Highlights

  • Consistent revenue growth, reaching $183.5 million in 2022, driven by a diversified product portfolio.
  • Strong profitability, with net income of $35.0 million in 2022 and healthy operating margins.
  • Robust balance sheet with $346 million in cash, cash equivalents, and investments as of December 31, 2022.
  • Shareholder-friendly capital allocation, with $146 million in dividends paid and $258 million in share repurchases in 2022.

Competitive Positioning

  • Specialized product offerings in niche medical device segments, providing a competitive advantage.
  • Established brand reputation and customer loyalty in its core markets.
  • Exposure to regulatory and reimbursement risks inherent in the medical device industry.
  • Relatively small market share compared to larger competitors, but a strong player in its specific market segments.

Growth Prospects

  • Ongoing investments in research and development to drive product innovation and maintain a competitive edge.
  • Capacity expansion projects, including a $250 million facility investment, to support anticipated growth in demand.
  • Potential for strategic acquisitions or partnerships to expand product offerings and market reach.
  • Exposure to global markets, with 41% of revenues coming from outside the United States in 2021.

Overall, Atrion Corporation’s consistent financial performance, strong balance sheet, diversified product portfolio, and commitment to growth and shareholder returns make it an attractive long-term investment opportunity in the medical device industry, despite the inherent risks associated with the sector.

Back to Table of Contents

Valuation Analysis

PE Ratio

The PE ratio for the company ATRI is as follows:
– Low: 30.25237407650973
– Base: 35.21074724097524
– High: 40.169120405440744

PB Ratio

The PB ratio for the company ATRI is as follows:
– Low: 3.5867126008563
– Base: 5.177913774688115
– High: 6.769114948519929

EPS Growth

The EPS growth for the company ATRI is as follows:
– Low: -10.40%
– Medium: -3.98%
– High: -0.01%

DPS Growth

The DPS growth for the company ATRI is as follows:
– Low: 10.35%
– Medium: 10.86%
– High: 11.36%

Unable to provide price targets since this company’s financials are highly unstable. We recommend not to hold this stock in your portfolio.

Back to Table of Contents

Industry and Competitors Analysis

Industry Overview

ATRI operates in the medical instruments and supplies industry, which includes companies that develop, manufacture, and sell various medical devices and equipment used in healthcare settings. Key competitors in this industry include Akoya Biosciences (AKYA), AtriCure (ATRC), ICU Medical (ICUI), Haemonetics Corporation (HAE), AngioDynamics (ANGO), NanoString Technologies (NSTG), AptarGroup (ATR), KORU Medical Systems (KRMD), The Cooper Companies (COO), Merit Medical Systems (MMSI), and Envista Holdings Corporation (NVST).

ATRI’s Competitive Positioning

ATRI is a relatively small player in the industry with a market capitalization of around $810 million and 712 full-time employees. The company specializes in fluid delivery, cardiovascular, and ophthalmology products, including valves, catheters, and other medical devices. ATRI’s financial performance has been stable, with consistent revenue growth and profitability over the past few years.

Compared to larger competitors like ICU Medical, Haemonetics, and The Cooper Companies, ATRI has a smaller market share and more specialized product offerings. However, ATRI’s focus on niche medical device segments and its established brand reputation in those areas could provide a competitive advantage.

Overall, while ATRI is a relatively small player in the broader medical instruments and supplies industry, its specialized product offerings and financial stability position it as a notable competitor in its specific market segments.

Back to Table of Contents

Chart of Competitors

"Chart of Competitors"

Back to Table of Contents

Financial Analysis

Financial Strength

The company has a very strong current ratio, consistently above 6, indicating it has ample liquidity to cover short-term obligations. It has zero debt, with a debt-to-equity ratio of 0, suggesting a very strong balance sheet. Return on equity and return on assets are generally healthy, in the range of 3-5%, though they have declined somewhat in recent quarters.

Potential for Growth

Revenue growth has been inconsistent, with some quarters showing declines and others showing moderate growth. The 3-year revenue growth per share has been relatively low, around 0-5% in recent years, indicating modest growth prospects. Operating cash flow growth has been volatile, with some quarters showing significant increases and others showing declines.

Competitive Advantage

The company appears to have pricing power, as evidenced by its ability to maintain relatively high gross profit margins (around 50-60%). Its debt-free balance sheet and strong liquidity position could be a competitive advantage.

Quality of Management

Management appears to be focused on maintaining a strong balance sheet and liquidity position. The inconsistent revenue growth and volatile operating cash flow growth could be areas of concern regarding management’s execution.

Shareholder Friendliness

The company pays a dividend, though the dividend yield is relatively low (around 0.3-0.6%). The payout ratio is generally below 50%, suggesting a reasonable balance between dividends and reinvestment. Share buybacks do not appear to be a significant part of the company’s capital allocation strategy.

Valuation

The price-to-earnings ratio has been relatively high, often above 30, suggesting that the stock may be richly valued. The price-to-book ratio has also been elevated, typically above 4, which could indicate that the stock is trading at a premium to its book value.

Overall, Atrion Corporation appears to be a financially strong company with a competitive advantage in its pricing power and debt-free balance sheet. However, its growth prospects seem modest, and its valuation metrics suggest that the stock may be richly valued. Management’s focus on maintaining a strong balance sheet is commendable, but the inconsistent revenue growth and volatile operating cash flow could be areas of concern.

Back to Table of Contents

Chart of Key Per Share Metrics

"Chart of Key Per Share Metrics"

Back to Table of Contents

Chart of Absolute Metrics

"Chart of Absolute Metrics"

Back to Table of Contents

Earnings Call Multi-Year Analysis

The company has not held any earnings calls in the past few years, making it difficult to conduct a comprehensive multi-year analysis. Without access to the transcripts or recordings of these calls, it is challenging to assess the company’s historical performance, management’s commentary, and any insights that could be gleaned from these events.

Key Takeaways and Implications

Due to the lack of available earnings call data, there are no meaningful key takeaways or implications that can be derived from a multi-year analysis. The absence of this information makes it challenging to evaluate the company’s communication with investors, its transparency, and any potential trends or patterns that could inform the overall financial analysis.

Recommendations and Future Considerations

Without the necessary earnings call data, it is not possible to provide any meaningful recommendations or considerations for the future. The company’s decision to forgo these investor communication events limits the ability to gain a deeper understanding of its financial performance, strategic direction, and management’s perspective on the business.

Back to Table of Contents

Financial Statements Multi Year

Revenue Growth and Diversification

Atrion has demonstrated consistent revenue growth over the years, with a diversified product portfolio across fluid delivery, cardiovascular, ophthalmology, and other segments. This diversification helps mitigate risks and provides a solid foundation for future growth.

Profitability and Margins

While Atrion has been consistently profitable, with growing net income, there have been periods of margin compression due to higher manufacturing costs or product mix changes. Maintaining profitability and managing costs will be crucial for long-term success.

Strong Financial Position

Atrion has a robust balance sheet with significant cash reserves, low debt levels, and access to a large credit facility. This strong liquidity position provides financial flexibility to fund growth initiatives, capital expenditures, and shareholder returns.

Shareholder-Friendly Capital Allocation

Atrion has a track record of returning capital to shareholders through consistent dividend payments and share repurchases, demonstrating a commitment to enhancing shareholder value.

Investments in Growth

The company has been investing in research and development, as well as capacity expansions, to drive future growth and maintain its competitive edge in the medical device industry.

Regulatory and Reimbursement Risks

As a medical device manufacturer, Atrion faces inherent risks related to regulatory oversight and potential changes in healthcare reimbursement policies, which could impact its operations and financial performance.

Global Presence and Diversification

Atrion has a significant international presence, with a substantial portion of its revenues coming from outside the United States, providing geographic diversification and exposure to global markets.

Overall, Atrion’s consistent financial performance, strong balance sheet, diversified product portfolio, and commitment to growth and shareholder returns make it an attractive long-term investment opportunity in the medical device industry, despite the inherent risks associated with the sector.

Back to Table of Contents

Insider Trading Analysis

Long-Term Patterns

The CEO (Battat David A) and CFO (Battat Emile A) have consistently been awarded and accumulated a large number of shares and stock options over the years, indicating their long-term commitment to the company. Other key executives like STUPP JOHN P JR, MORGAN HUGH J JR, and STRICKLAND JEFFERY have also been granted and accumulated shares and options, though to a lesser extent compared to the CEO and CFO. There have been occasional sales by executives, but the overall trend shows a net increase in insider ownership over the long-term.

Short-Term Patterns

In the most recent 2-3 years, there have been a number of restricted stock unit and deferred stock unit awards to executives, indicating a focus on long-term incentives. The CEO and CFO have made some open market purchases of shares in the past, signaling their confidence in the company’s prospects. There have been a few isolated instances of executives selling shares, but the volumes have been relatively small compared to their overall holdings.

Implications

The consistent accumulation of shares and options by the CEO, CFO, and other key executives suggests strong long-term alignment between insiders and shareholders. The recent focus on restricted and deferred stock units indicates a desire to incentivize executives to create sustainable long-term value. The limited selling activity and occasional open market purchases by insiders signal that they are bullish on the company’s future performance.

Overall, the insider trading patterns at Atrion Corporation point to a management team that is heavily invested in the long-term success of the company, both financially and strategically. This should be reassuring for long-term investors, while the short-term trading activity suggests limited near-term concerns from insiders.

Back to Table of Contents

Management Compensation Benchmark Analysis

Compensation Structure

The compensation for ATRI’s executives appears to be heavily weighted towards base salary, with the base salary portion making up on average 50.20% of the total compensation across all years and executives reported. This suggests the compensation structure is not heavily incentive-based, which may not fully align the executives’ interests with long-term shareholder value creation.

Lack of Performance-Based Pay

The reported compensation details show minimal to no bonus, stock awards, or incentive plan compensation for ATRI’s executives. This lack of performance-based pay components may not provide strong enough incentives for the executives to drive long-term company performance and shareholder value.

Consistency in Compensation

The compensation for the Chairman, CEO, and other key executives has remained relatively consistent over the years, with only modest changes in total compensation amounts. This stability in compensation may indicate a more conservative approach that does not heavily incentivize significant outperformance.

Benchmarking to Other Companies

Comparing ATRI’s executive compensation structure to that of other companies like AKYA, ATRC, ICUI, and HAE, ATRI’s compensation appears to be more heavily weighted towards base salary and less focused on performance-based pay components. This may be an area for ATRI to consider adjusting to better align with industry practices and shareholder interests.

In summary, a long-term investor in ATRI may want to evaluate whether the company’s executive compensation structure provides sufficient incentives for the leadership team to drive sustained long-term growth and shareholder value creation. Exploring ways to increase the performance-based components of the compensation plan could be an area of focus for the company to consider.

Back to Table of Contents

Proxy Statement Analysis

Business Strengths

The following analysis is based on the latest proxy statement of ATRI. The overview focused more on Atrion’s business strengths like its patent portfolio, capital investments, margin opportunities, recurring revenue streams, and exposure to attractive medical end markets. While these factors can contribute to long-term value creation, assessing compensation alignment requires specifics on the structure of executive pay packages – such as the balance between short-term and long-term incentives, equity grants that vest over multiple years, performance metrics tied to shareholder returns, etc.

Limitations of Analysis

Unfortunately, based on the information provided, I do not have enough details about Atrion Corporation’s executive compensation plans or policies to determine if they are well-aligned with creating long-term shareholder value. Without those compensation details, I cannot provide a confident evaluation of whether the executives are incentivized appropriately for sustainable long-term value growth versus short-term priorities. My analysis is limited to highlighting the company’s positive business fundamentals that could enable long-term success if complemented by a well-designed compensation approach.

Back to Table of Contents

News Analysis

Acquisition Announcement

On May 28, 2024, Atrion Corporation entered into a merger agreement to be acquired by Nordson Corporation. This is a significant event that could lead to a change in the company’s operations, management, and future prospects.

Dividend Increases

Atrion has a consistent track record of increasing its quarterly cash dividend over the years, indicating a commitment to returning value to shareholders. The most recent increase was announced on August 22, 2023.

Quarterly Financial Results

The company regularly reports its quarterly and annual financial results, providing insights into its performance, revenue, earnings, and growth trends.

Analyst Coverage

Various analysts have initiated coverage or provided recommendations on Atrion’s stock, with some expressing concerns about the proposed acquisition and others investigating whether the deal offers a fair price to shareholders.

While the acquisition announcement is a significant development, long-term investors should carefully evaluate the terms of the deal, the potential synergies, and the strategic rationale behind the merger. Additionally, Atrion’s consistent dividend growth and financial performance over the years could be factors to consider for investors focused on income and stability.

However, it’s important to note that the sentiment and potential impact can change rapidly based on new developments, regulatory approvals, and market conditions. Long-term investors should conduct their own due diligence, consult with financial advisors, and make informed decisions based on their investment objectives and risk tolerance.

Back to Table of Contents

Technical Indicators Analysis

Next Week Trading

The recent price action and technical indicators suggest a potentially volatile trading week ahead. The TEMA (Triple Exponential Moving Average) has been declining, indicating a possible bearish trend in the short-term. The RSI (Relative Strength Index) is around 50, suggesting the stock is neither overbought nor oversold, leaving room for potential price swings. Traders should closely monitor the support and resistance levels discussed below and be prepared for potential volatility in the coming week.

Resistance and Support Levels

The 20-day SMA (Simple Moving Average) at around $457 and the 50-day SMA at around $437 could act as key resistance levels. The 200-day SMA at around $389 could provide support. Traders should watch these levels closely for potential breakouts or breakdowns.

Short-Term Investor

The recent decline in the TEMA and the RSI around 50 suggest a neutral to slightly bearish short-term outlook. Short-term investors may consider taking a cautious approach, waiting for a clearer trend to emerge before taking positions. Monitoring the support and resistance levels mentioned above could help identify potential entry and exit points.

Long-Term Investor

The long-term trend appears relatively positive, with the 200-day SMA at $389 providing a solid support level. However, the recent volatility and the potential for short-term bearishness should be considered. Long-term investors may want to hold their positions, but also be prepared to add to their positions on any significant dips towards the 200-day SMA support level.

Overall, the technical indicators suggest a mixed outlook, with the potential for short-term volatility and a need to closely monitor the support and resistance levels. Investors should adjust their strategies accordingly, based on their risk tolerance and investment horizon.

Back to Table of Contents

Chart of Valuation History

"Chart of Valuation History"

Back to Table of Contents

Financial Statements Annual

Financial Statements Annual 2024 Q2

Revenues decreased 8% in 2023 to $169.3 million, primarily due to lower sales volumes across most product lines. Fluid Delivery revenues decreased 15%, Cardiovascular revenues increased 3%, and Ophthalmic revenues increased 48%.

Profitability

Gross profit margin decreased from 41% in 2022 to 37% in 2023, due to higher manufacturing costs. Operating income decreased from $397 million in 2022 to $226 million in 2023, with the operating margin declining from 22% to 13%. Net income decreased from $350 million in 2022 to $194 million in 2023, with earnings per share declining from $19.59 to $11.02.

Cash Flows and Liquidity

Cash and investments decreased by $201 million to $144 million, primarily due to $223 million in capital expenditures and $153 million in dividend payments. The company has a $250 million revolving credit facility, which was undrawn as of December 31, 2023. Working capital increased slightly to $102.1 million, with the current ratio remaining strong at 9.1.

Capital Allocation

The company paid $153 million in dividends in 2023 and expects to continue funding future dividends from operating cash flows. The company repurchased $1.7 million of its own shares in 2023, with $12.9 million remaining under the existing repurchase authorization.

Operational Highlights

The company completed a $270 million expansion project at one of its facilities in 2023. Research and development expenses increased 22% to $6.7 million, as the company continues to invest in new product development. The company identified a material weakness in its internal controls related to inventory count procedures at one of its subsidiaries, which it is working to remediate.

Overall, the financial statements indicate that Atrion faced some headwinds in 2023, with lower revenues and profitability, but the company maintains a strong balance sheet and liquidity position to support its ongoing operations and strategic initiatives.

Financial Statements Annual 2023 Q2

Consistent Revenue and Earnings Growth

Atrion has demonstrated consistent growth in revenues, which increased from $147.6 million in 2020 to $165.0 million in 2021 and $183.5 million in 2022. Net income has also grown steadily from $32.1 million in 2020 to $33.1 million in 2021 and $35.0 million in 2022. This consistent financial performance over the past 3 years is a positive indicator for long-term investors.

Diversified Product Portfolio

Atrion has a diversified product portfolio serving the fluid delivery (46% of 2022 revenues), cardiovascular (37% of 2022 revenues), and ophthalmic (3% of 2022 revenues) markets. This diversification helps mitigate risks from any single product line or market segment.

Strong Balance Sheet and Cash Flows

Atrion has a strong balance sheet with $346 million in cash, cash equivalents, and investments as of December 31, 2022. The company generated $288 million in operating cash flow in 2022, which provides ample liquidity to fund growth initiatives, capital expenditures, and shareholder returns.

Shareholder-Friendly Capital Allocation

Atrion has a history of returning capital to shareholders through dividends and share repurchases. The company paid $146 million in dividends in 2022 and repurchased $258 million of its own stock. This demonstrates a commitment to enhancing shareholder value.

Ongoing Investment in R&D and Capacity Expansion

Atrion is investing in its future growth through R&D spending ($5.5 million in 2022) and a $250 million expansion project at one of its facilities. These investments position the company to maintain its competitive edge and meet growing demand.

Exposure to Regulatory and Reimbursement Risks

As a medical device manufacturer, Atrion is subject to extensive regulatory oversight and potential changes in healthcare reimbursement policies, which could impact the company’s operations and financial performance.

Overall, Atrion’s consistent financial performance, diversified product portfolio, strong balance sheet, and shareholder-friendly capital allocation make it an attractive long-term investment opportunity, though the company faces inherent risks associated with the medical device industry.

Financial Statements Annual 2022 Q2

Revenue Growth

Atrion’s revenues have grown from $514 million in 2000 to $1.65 billion in 2021, representing a significant increase over the past 21 years.

Profitability

Atrion has been consistently profitable, with net income increasing from $28 million in 2000 to $331 million in 2021. The company’s operating income margin was 22% in 2021.

Diversified Product Portfolio

Atrion has a diverse product portfolio, with fluid delivery (47% of 2021 revenues), cardiovascular (34%), ophthalmology (4%), and other products (15%). This diversification has helped the company navigate changing market conditions.

International Presence

Approximately 41% of Atrion’s revenues in 2021 were from outside the United States, demonstrating its global reach.

Strong Financial Position

Atrion had $807 million in cash, cash equivalents, and investments as of December 31, 2021, providing ample liquidity. The company has a $750 million revolving credit facility, which was undrawn at the end of 2021.

Capital Allocation

Atrion has consistently invested in research and development, with R&D expenses of $5.7 million in 2021. The company has also returned capital to shareholders through dividends and share repurchases, spending $170 million on share buybacks in 2021.

Expansion Plans

Atrion is expanding one of its manufacturing facilities at an estimated cost of $250 million, which is expected to be completed in the first half of 2023 to support anticipated increases in capacity.

COVID-19 Impact

The COVID-19 pandemic has had some negative impacts on Atrion’s operations, including delays and disruptions in its supply chain and manufacturing processes, as well as reduced demand for certain products. However, the company has been able to navigate these challenges thus far.

Overall, Atrion appears to be a well-managed, financially strong medical device company with a diversified product portfolio, international presence, and a track record of consistent growth and profitability. The company’s expansion plans and ability to navigate the COVID-19 pandemic suggest a positive long-term outlook.

Back to Table of Contents

Financial Statements Quarterly

Financial Statements Quarterly 2024 Q2

Revenue Growth

Atrion reported revenues of $47.3 million in Q1 2024, an 18% increase compared to $40.0 million in Q1 2023. This was driven by strong performance across its product lines, including a 27.8% increase in Cardiovascular revenue, 11.1% increase in Fluid Delivery revenue, 8.6% increase in Ophthalmology revenue, and 17.1% increase in Other product line revenue.

Profitability Decline

Despite the revenue growth, Atrion’s operating income declined 30% to $31.1 million in Q1 2024 from $44.7 million in Q1 2023. This was primarily due to a 40.4% increase in cost of goods sold, which outpaced the revenue growth. The gross profit margin declined from 37.7% in Q1 2023 to 26.1% in Q1 2024, largely due to higher manufacturing costs including a $23 million one-time inventory write-off.

Strong Liquidity and Cash Flow

Atrion maintained a strong liquidity position with $187 million in cash, cash equivalents, short-term and long-term investments as of March 31, 2024. The company generated $115 million in cash from operating activities in Q1 2024, which it used to fund $38 million in dividends, $36 million in investments, and $32 million in capital expenditures.

Dividend Payments

Atrion continued its track record of returning capital to shareholders, paying $2.20 per common share in dividends during Q1 2024, up from $2.15 per share in the prior year period.

Regulatory and Competitive Landscape

The financial statements do not indicate any significant changes in the regulatory or competitive environment that could impact Atrion’s business in the long-term. The company continues to focus on product innovation, cost control, and maintaining its strong market position in the medical device industry.

Overall, Atrion demonstrated solid revenue growth in Q1 2024, but profitability declined due to higher manufacturing costs. The company’s strong liquidity and cash flow position provide it with the financial flexibility to navigate the current operating environment and invest in future growth opportunities.

Financial Statements Quarterly 2024 Q1

Revenue Decline

Atrion’s revenues declined by 6% in Q3 2023 compared to Q3 2022, and by 10.6% in the first 9 months of 2023 compared to the same period in 2022. This was primarily driven by decreases in the Fluid Delivery (down 18.2% in Q3 and 19.1% YTD) and Other product lines (down 37.7% in Q3 and 29.9% YTD).

Profitability Squeeze

Gross profit margin declined from 39.6% in Q3 2022 to 32.8% in Q3 2023, and from 41.0% in the first 9 months of 2022 to 36.6% in the same period of 2023. This was due to higher manufacturing costs. As a result, operating income declined by 57.7% in Q3 and 48.5% in the first 9 months of 2023 compared to the prior year periods.

Liquidity and Capital Resources

Atrion had $140 million in cash, cash equivalents, and investments as of September 30, 2023, down from $346 million at the end of 2022. The company has a $750 million revolving credit facility, of which $45 million was drawn as of Q3 2023. Management believes the company’s liquidity position and access to financing are sufficient to fund its cash requirements for the foreseeable future.

Shareholder Returns

Atrion paid $3.88 per share in dividends in Q3 2023 and $6.50 per share in the first 9 months of 2023, up from $3.41 and $6.05 per share in the respective prior year periods. The company also repurchased $1.7 million worth of its own shares in the first 9 months of 2023.

In summary, Atrion faced revenue and profitability headwinds in 2023 so far, but maintains a strong liquidity position and continues to return capital to shareholders through dividends and share repurchases. The company’s ability to manage costs and navigate the current market environment will be key going forward.

Financial Statements Quarterly 2023 Q4

Revenue Decline

Atrion’s revenues declined 10% in Q3 2023 compared to Q3 2022, from $48.9 million to $43.8 million. This was primarily due to decreased sales volumes in the Fluid Delivery and Other product lines.

Profitability Decline

Atrion’s operating income declined 33% in Q3 2023 compared to Q3 2022, from $11.0 million to $7.4 million. Net income declined 30% from $9.3 million to $6.6 million. The decline in profitability was driven by lower sales volumes and higher manufacturing costs.

Margin Compression

Atrion’s gross profit margin declined from 42.6% in Q3 2022 to 39.4% in Q3 2023, due to the higher manufacturing costs. Operating margin also declined from 22.6% to 16.8% over the same period.

Inventory Build-up

Atrion’s inventory increased from $65.8 million at the end of 2022 to $80.3 million at the end of Q3 2023, as customers worked to bring their inventories to appropriate levels.

Strong Liquidity

Atrion had $156 million in cash, cash equivalents, and investments at the end of Q3 2023, along with $712 million in available borrowing capacity under its credit facility. This provides ample liquidity to fund operations and investments.

Dividend Payments

Atrion paid $3.8 million in dividends to shareholders in Q3 2023, reflecting its commitment to returning capital to shareholders.

In summary, Atrion faced headwinds in Q3 2023 with declining revenues and profitability, but maintains a strong financial position with ample liquidity to weather the current challenges. The company’s focus on cost control and capital allocation will be critical going forward.

Financial Statements Quarterly 2023 Q3

Revenue Decline

Atrion’s revenues declined 15% year-over-year in Q1 2023, from $47.1 million to $40.0 million. This was primarily due to several customers unexpectedly pushing out deliveries, citing concerns about a global economic slowdown.

Profitability Decline

Atrion’s operating income declined 56% year-over-year, from $10.3 million to $4.5 million. Net income declined 59%, from $8.5 million to $3.5 million. This was driven by the lower sales volumes and higher operating expenses.

Gross Margin Compression

Atrion’s gross profit margin declined from 40.8% in Q1 2022 to 37.7% in Q1 2023, due to higher manufacturing costs and product mix changes.

Strong Balance Sheet and Liquidity

Atrion has a very strong balance sheet, with $263 million in cash, cash equivalents, and investments as of March 31, 2023. This, along with its $750 million credit facility, provides ample liquidity to fund operations and investments.

Capital Allocation

Atrion continues to return capital to shareholders through dividends ($3.8 million in Q1 2023) and share repurchases ($0.6 million in Q1 2023). The company has a history of prudent capital allocation.

Overall, the Q1 2023 results show some near-term headwinds, with revenue and profitability declining. However, Atrion’s strong financial position, diversified product portfolio, and disciplined capital allocation provide a solid foundation for long-term investors. The company’s ability to navigate economic cycles and maintain its competitive position will be key going forward.

Back to Table of Contents

Earnings Call Analysis

Back to Table of Contents

The information provided on this blog is for informational purposes only and should not be considered as financial advice. You should consult with a qualified financial professional before making any investment decisions. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal.